Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:AIM NASDAQ:CRDL CVE:GPH CVE:WMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$0.29+3.2%$0.43$0.21▼$20.35$4.27M1.1816.15 million shs781,918 shsCRDLCardiol Therapeutics$1.07+0.5%$1.23$0.88▼$1.71$122.74M0.72516,742 shs289,217 shsGPHGraphite OneC$1.00C$1.12C$0.65▼C$2.57C$208.97M1.237977294,179 shs104,996 shsWMDWeedMDC$0.28-1.8%C$0.28C$0.23▼C$0.99C$67.82MN/A766,591 shs271,436 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech-4.12%-21.78%-30.36%-48.36%-96.71%CRDLCardiol Therapeutics+2.91%+0.95%-13.11%-24.29%-22.06%GPHGraphite One+2.04%-0.99%-14.53%-18.37%+40.85%WMDWeedMD0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$0.29+3.2%$0.43$0.21▼$20.35$4.27M1.1816.15 million shs781,918 shsCRDLCardiol Therapeutics$1.07+0.5%$1.23$0.88▼$1.71$122.74M0.72516,742 shs289,217 shsGPHGraphite OneC$1.00C$1.12C$0.65▼C$2.57C$208.97M1.237977294,179 shs104,996 shsWMDWeedMDC$0.28-1.8%C$0.28C$0.23▼C$0.99C$67.82MN/A766,591 shs271,436 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech-4.12%-21.78%-30.36%-48.36%-96.71%CRDLCardiol Therapeutics+2.91%+0.95%-13.11%-24.29%-22.06%GPHGraphite One+2.04%-0.99%-14.53%-18.37%+40.85%WMDWeedMD0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00Buy$9.002,971.67% UpsideCRDLCardiol Therapeutics 2.33Hold$8.50698.12% UpsideGPHGraphite One 3.00BuyC$2.85185.00% UpsideWMDWeedMD 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest WMD, AIM, GPH, and CRDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026CRDLCardiol Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/1/2026AIMAIM ImmunoTech Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $9.004/6/2026CRDLCardiol Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.00(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$90K47.40N/AN/A($2.99) per share-0.10CRDLCardiol TherapeuticsN/AN/AN/AN/A$0.11 per shareN/AGPHGraphite OneN/AN/AC$0.01 per share94.17C$0.51 per shareN/AWMDWeedMDC$27.53M2.46C$0.08 per share3.27C$0.34 per share0.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$13.96M-$24.68N/AN/AN/A-14,123.40%N/A-177.72%N/ACRDLCardiol Therapeutics-$24.20M-$0.28N/AN/AN/AN/A-229.43%-165.60%8/13/2026 (Estimated)GPHGraphite One-C$4.90M-C$0.07N/AN/AN/AN/A-14.13%-6.61%N/AWMDWeedMDN/A-C$0.42N/AN/AN/AN/AN/AN/AN/ALatest WMD, AIM, GPH, and CRDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026AIMAIM ImmunoTechN/A-$0.69N/A-$0.69N/A$0.02 million5/11/2026Q1 2026CRDLCardiol Therapeutics-$0.07-$0.07N/A-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/AGPHGraphite OneN/AN/AN/AN/AN/AWMDWeedMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.101.011.01CRDLCardiol TherapeuticsN/A4.394.39GPHGraphite One0.1330.040.33WMDWeedMD95.633.461.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%CRDLCardiol Therapeutics12.49%GPHGraphite One0.13%WMDWeedMDN/AInsider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.95%CRDLCardiol Therapeutics5.25%GPHGraphite One28.81%WMDWeedMDN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech2014.56 million14.43 millionNot OptionableCRDLCardiol Therapeutics20115.25 million109.20 millionNot OptionableGPHGraphite One20208.97 millionN/ANot OptionableWMDWeedMD628246.62 millionN/ANot OptionableWMD, AIM, GPH, and CRDL HeadlinesRecent News About These CompaniesENTG:CA Entourage Health Corp.October 19, 2024 | seekingalpha.comHurricane Helene by the numbers: Catastrophic destruction covers 400 milesOctober 4, 2024 | abcnews.go.comWMDH WMD Holdings Group, Inc.September 27, 2024 | seekingalpha.comEthics and Weapons of Mass DestructionAugust 8, 2024 | cambridge.orgC'Truth about WMD will finally emerge'March 4, 2024 | dailymail.co.ukNo cabinet submission on costs, benefits, implications of going to war in IraqJanuary 3, 2024 | theaustralian.com.auBlair: 'Saddam still has weapons of mass destruction'October 4, 2023 | dailymail.co.ukBush administration retreats on WMD claimAugust 29, 2023 | namibian.com.naNMissing WMD ‘hurting war on terror’August 29, 2023 | namibian.com.naNWeapons of Mass Destruction and the ethics of their usageAugust 17, 2023 | arstechnica.comARussia used sabotaged dam as ‘weapon of mass destruction’ says UkraineJune 12, 2023 | politico.euPUS, South Korea issue fresh North Korea sanctions on 'illicit' IT workforceMay 27, 2023 | asahi.comAMalaysia Gets Tough on WMDMay 27, 2023 | thediplomat.comTInterpol Tackles WMD TerrorismMay 21, 2023 | thediplomat.comT'Weapons of mass destruction found'May 20, 2023 | dailymail.co.ukChemical Weapons are NOT WMDsMay 17, 2023 | thediplomat.comTThe Next Financial WMD?May 14, 2023 | thestreet.comThe Week in Weed – May 6, 2023 - StratCannMay 6, 2023 | news.google.comNWMD in Iraq: Evidence and ImplicationsApril 28, 2023 | medscape.comMWhat happened when WMD experts tried to make the GPT-4 AI do bad thingsApril 1, 2023 | thebulletin.orgTNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026A Market Rotation Toward Quality Will Benefit These 3 ETFsBy Nathan Reiff | June 8, 2026Burger King’s Turnaround Is Putting Restaurant Brands Back in FocusBy Peter Frank | July 1, 2026Qualcomm’s $4B AI Deal Takes Aim at NVIDIA’s Software MoatBy Jeffrey Neal Johnson | June 25, 2026Meta’s WhatsApp Shakeup Could Put India at the Center of Its Next Growth PushBy Leo Miller | July 1, 2026WMD, AIM, GPH, and CRDL Company DescriptionsAIM ImmunoTech NYSEAMERICAN:AIM$0.29 +0.01 (+3.17%) As of 03:38 PM Eastern This is a fair market value price provided by Massive. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Cardiol Therapeutics NASDAQ:CRDL$1.06 +0.01 (+0.47%) As of 03:38 PM Eastern This is a fair market value price provided by Massive. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Graphite One CVE:GPHC$1.00 0.00 (0.00%) As of 06/30/2026 03:59 PM EasternGraphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.WeedMD CVE:WMDC$0.28 -0.01 (-1.79%) As of 07/15/2021WeedMD Inc. produces, distributes, and sells medical-grade cannabis in Canada. It offers dried cannabis, cannabis plants and seeds, cannabis oil, edibles, extracts and topicals, and others, as well as cannabis flower products. The company sells its products directly to medical patients and strategic relationships across the seniors' market, as well as through supply agreements with Shoppers Drug Mart and six provincial distribution agencies under the Color Cannabis, Saturday, Starseed, and WeedMD brand names. WeedMD Inc. is headquartered in Aylmer, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks AirJoule Unveils Prime System, Clearing Path to Commercialization Comcast’s NBCUniversal Split Puts Broadband Back in Focus Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets Ouster Is Breaking Out as a Physical AI Leader: Here's What's Driving the Move Meta’s WhatsApp Shakeup Could Put India at the Center of Its Next Growth Push Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
